Genmab (NASDAQ: GMAB)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Genmab (NASDAQ: GMAB) through any online brokerage.
The latest price target for Genmab (NASDAQ: GMAB) was reported by Morgan Stanley on Tuesday, May 17, 2022. The analyst firm set a price target for 29.00 expecting GMAB to fall to within 12 months (a possible -5.94% downside). 12 analyst firms have reported ratings in the last year.
The stock price for Genmab (NASDAQ: GMAB) is $30.83 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Genmab.
Genmab’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Genmab.
Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.